14 results about "Diosgenin" patented technology

This invention discloses a biphasic combined Lewis acid hydrolysis method for extracting diosgenin from fenugreek, belonging to the field of natural product extraction technology. The extraction method disclosed in this invention includes: defatting fenugreek raw material, mixing it with a biphasic reaction system composed of Lewis acid, concentrated hydrochloric acid, methanol, water, and petroleum ether, and carrying out a hydrolysis reaction under heating conditions. After the reaction, the organic phase is separated, concentrated, and dried to obtain diosgenin. This invention innovatively introduces a Lewis acid catalyst into the biphasic acid hydrolysis system of fenugreek, achieving significant results such as a 25% reduction in reaction time, a 50% reduction in concentrated hydrochloric acid usage, and a 25% reduction in water usage while ensuring the extraction rate of diosgenin. This method has advantages such as mild conditions, low acid consumption, short processing time, and environmental friendliness, and is suitable for the large-scale green production of diosgenin.

This invention discloses the application of plant extracts in the preparation of drugs that inhibit canine parvovirus, belonging to the field of biomedical technology. The plant extract is at least one selected from phlorizin, neomethylhesperidin-dihydrochalcone, tribulus terrestris saponin, stevia glycoside, soy isoflavones, berberine hydrochloride, diosgenin, and silymarin. Through in-depth research on various plant extracts, this invention has found that phlorizin, neomethylhesperidin-dihydrochalcone, tribulus terrestris saponin, stevia glycoside, soy isoflavones, berberine hydrochloride, diosgenin, and silymarin all exhibit significant inhibitory effects on canine parvovirus, with soy isoflavones showing particularly outstanding effects. This research provides a novel natural drug option for the prevention and treatment of canine parvovirus. This invention not only expands the application scope of natural plant extracts in the veterinary medicine field but also provides important technical support for the development of novel, highly effective, safe, and side-effect-free drug formulations for the prevention and treatment of canine parvovirus.

The invention provides a method for preparing 5 alpha-hydroxyl laxogenin by a one-pot method, which comprises the following steps: S1) dissolving diosgenin in a mixture of an organic solvent and water, adding a halogenating reagent, and heating for reaction after dissolving to obtain a dihydroxylation intermediate; s2) adding an oxidizing agent into the reaction liquid obtained in the step S1), adding a quenching agent after reaction, adding a mixture of an organic solvent and water after vacuum concentration, pulping, filtering and drying to obtain a 5 alpha-hydroxyl laxogenin crude product; s3) adding a pulping solvent into the crude product obtained in the step S2), heating, pulping and filtering to obtain a wet product; and adding a recrystallization solvent into the wet product, heating for dissolving, dropwise adding a crystallization solvent for crystallization, carrying out gradient cooling, filtering, and drying to obtain the 5 alpha-hydroxy laxogenin. The method avoids introducing a protecting group, so that the reaction route is greatly shortened; reaction intermediates do not need to be separated and purified, reaction procedures are reduced, and production cost is reduced; the refined finished product is relatively high in purity and stable in quality; the reaction conditions are mild.

The embodiment of the invention discloses a synthesis method of a diosgenin derivative Anzurogenin D. The diosgenin derivative Anzurogenin D is shown in the description. The method comprises the following steps: (1) dropwise adding an oxidizing agent into a system of diosgenin, a catalyst and an organic solvent, continuously reacting after dropwise adding, then adding a quenching agent for quenching reaction, then adding a dispersing solvent and water, filtering and drying to obtain an Anzurogenin D crude product; and (2) carrying out pulping and refining treatment on the Anzurogenin D crude product, so as to obtain an Anzurogenin D finished product. By introducing the transition metal catalyst, the use of a strong oxidant is avoided, so that the reaction conditions are milder and more controllable; the dihydroxylation reaction is completed in one step, the introduction of a protecting group is avoided, and the atom economy of the process is relatively good; the finished product is high in purity and stable in quality; the used raw materials are cheap, easy to obtain and environment-friendly, the whole process is simple and controllable, and the method is suitable for large-scale workshop production.

The application of diosgenin in the preparation of drugs for the prevention or treatment of acute kidney injury falls within the pharmaceutical field. Specifically, this invention discloses that diosgenin, by directly binding to the PIK3CA protein, regulates the PI3K / Akt-NF-κB pathway, inhibiting inflammatory responses, apoptosis, and pyroptosis in renal tubular epithelial cells, thereby alleviating kidney damage. Cellular experiments show that diosgenin at concentrations of 0.1–5 μM can significantly protect renal tubular epithelial cells; animal experiments show that doses of 1–20 mg / kg can significantly improve renal function and reduce pathological damage in mice with acute kidney injury. This invention clarifies a complete chain of evidence from "compound—target—pathway—efficacy," providing a new drug candidate for the treatment of acute kidney injury and offering a paradigm for the mechanistic study of active ingredients in traditional Chinese medicine, contributing to the transformation of traditional Chinese medicine from empirical medicine to evidence-based and molecular medicine.

This invention belongs to the field of natural product biosynthesis technology, specifically relating to a glycosyltransferase UGT73DY2, its encoding gene, and its applications. The diosgenin-3-O-α-L-pyranorhamnetose-(1→4)-[α-L-pyranorhamnetose]-(1→2)-β-D-glucoside and pennosapogenin-3-O-α-L-pyranorhamnetose-(1→4)-[α-L-pyranorhamnetose]-(1→2)-β-D-glucoside synthesized by the glycosyltransferase UGT73DY2 of this invention are key intermediate compounds in the biosynthesis of Paris polyphylla saponins II or VII. These compounds are synthesized in vitro under the catalytic action of glycosyltransferase UGT73DY2, laying the foundation for the industrial production of Paris polyphylla saponins II and VII. Meanwhile, a new Ophiopogon japonicus saponin compound can also be synthesized under the action of glycosyltransferase UGT73DY2, providing a new direction for further research on the application of glycosyltransferase UGT73DY2.

The invention discloses a novel medical application of diosgenin, and relates to an application of diosgenin in preparation of drugs for preventing and / or treating tanshinone addiction withdrawal. According to the method, the influence of the diosgenin on the core behavioral indications of the fluazinone addiction is evaluated through an animal model, wherein the influence comprises fluazinone-induced hypermental movement and a foraging behavior based on condition position preference. The result shows that the diosgenin can obviously inhibit the mental movement activity increase caused by the fluazinone, and can effectively reverse the foraging behavior with preferred conditions and positions. The diosgenin is proved to be capable of relieving the positive strengthening and mental movement stimulation effect of the fluazinone so as to effectively weaken the dependence and the desire on the fluazinone, and can be used for preventing and treating the fluazinone addiction. The invention provides a clear direction and an experimental basis for developing the anti-fluazinone addiction medicine taking the diosgenin as an active component, and has a good clinical application prospect.

This invention belongs to the field of biomedical technology, specifically relating to an umbilical cord MSC exosome nanocarrier delivery system and its application in the preparation of drugs for treating allergic rhinitis. This invention prepares the umbilical cord MSC exosome nanocarrier delivery system by adding a specific concentration of diosgenin to the culture medium of umbilical cord mesenchymal stromal cells (MSCs), collecting the cell culture supernatant, and separating and extracting it. Animal experiments show that the delivery system prepared in this invention significantly improves the symptoms of nose scratching and sneezing in mice with allergic rhinitis. Its mechanism of action lies in effectively regulating the Th1 / Th2 immune balance: significantly inhibiting the overexpression of the pro-inflammatory factor IL-4, while simultaneously restoring the anti-inflammatory factor IL-10, thus avoiding immune dysregulation. This invention provides a safe and effective new treatment for allergic rhinitis and has good clinical application prospects.

The invention belongs to the technical field of plant genetic engineering. The invention relates to a transcription factor, in particular to a Dioscorea composita DcAIL5 transcription factor and application thereof in increasing diosgenin content. The invention discloses the regulation and control effect of the Dioscorea composita transcription factor DcAIL5 in diosgenin biosynthesis for the first time, the accumulation of the diosgenin is obviously reduced by silencing the DcAIL5, and the accumulation of the diosgenin is obviously improved by transient overexpression. Therefore, the DcAIL5 can be used as a core target of genetic engineering and genetic improvement, is used for cultivating a new variety of Dioscorea composita with high saponin content, and is expected to relieve the supply and demand contradiction of steroid drug raw materials. The invention provides a new path for green, efficient and sustainable production of diosgenin, and has wide industrialization prospects and application values in the aspects of transgenic breeding, development of yield increasing reagents, molecular marker-assisted selection and the like.

The invention discloses a rhizoma polygonati compounded buffalo milk product and a preparation method thereof, and belongs to the technical field of dairy product processing. The compound buffalo milk comprises the following components in parts by weight: 80-95 parts of buffalo milk, 1-5 parts of rhizoma polygonati powder and 2-8 parts of rhizoma polygonati paste. The compound buffalo milk is prepared by the following steps: performing freezing superfine grinding on rhizoma polygonati powder, baking at 160-220 DEG C for 10-20 minutes, compounding with rhizoma polygonati paste and buffalo milk, and performing high-pressure homogenization and high-temperature pipeline instantaneous sterilization. Through cooperation with the technology, the final product of the compound milk in cooperation with the baked polygonatum sibiricum powder and the polygonatum sibiricum paste is high in flavor acceptability and rich in taste level, and the viscosity is increased. The content of polygonatum polysaccharide in the final product is larger than or equal to 0.5%, the content of diosgenin is larger than or equal to 0.01%, the in-vitro antioxidant activity is remarkably improved, and the quality stability is remarkably enhanced. The preparation method successfully solves the industrial problems of poor stability, poor flavor, low retention rate of active ingredients and the like when the rhizoma polygonati is blended into the dairy product.

The invention provides an application of diosgenin in preparation of a medicine for treating heart failure. In-vivo and in-vitro experiments prove that the diosgenin can be directly combined with heat shock protein HSP90 in a targeting manner, and can be used for effectively relieving myocardial hypertrophy caused by pressure load, inhibiting cardiac fibrosis and finally delaying the progress of heart failure by activating an HSP90 / LKB1 / AMPK signal axis, maintaining the mitochondrial function of myocardial cells and improving fatty acid metabolism for the first time. The discovery provides a new drug choice and a clear action target for the treatment of heart failure.

The invention discloses pilose antler polypeptide-diosgenin self-assembled nanoparticles as well as a preparation method and application thereof, and belongs to the technical field of natural medicine composite nanoparticles. The cornua cervi pantotrichum polypeptide-diosgenin self-assembled nano-particles are an amorphous state sphere-like compound formed by self-assembly of cornua cervi pantotrichum polypeptide and diosgenin. The self-assembled nano-particles are applied to the aspect of improving blood testis barrier injury caused by aging, solve the problems of low utilization efficiency of natural components and insufficient stability of the existing self-assembled nano-particles based on natural active components, and have the characteristics of good stability and high drug loading capacity.

The invention provides a combined marker combination as well as a detection method and a kit thereof. The combined marker combination comprises a plasma protein marker and a blood metabolism marker, the plasma protein marker comprises an adaptor protein PH-containing structural domain, enolase 3, a proline 4-hydroxylase alpha1 chain and ethanol dehydrogenase 1C, and the adaptor protein comprises an adaptor protein PH-containing structural domain, a proline 4-hydroxylase alpha1 chain and a proline 4-hydroxylase alpha2 chain. The blood metabolism marker is prepared from diosgenin, eicosapentaenoic acid, folinic acid, hydroxyprogesterone hexanoate, testosterone, perfluorooctane sulfonic acid, prasterone sulfate, androstane dienone, long pine needle ketone and 1-(22 carbon 4 enoyl) lysophosphatidylcholine. Through cooperative detection of protein-metabolism markers and combined application of a machine learning model, accurate prediction of the age-related disease risk is achieved, the cognitive decline risk can be pre-judged in advance, meanwhile, efficient synchronous detection of multiple markers is achieved by means of a liquid chromatography-tandem mass spectrometry synchronous detection technology, the sample dosage is small, the detection process is standardized, and the detection efficiency is high. The large-scale queue research requirement is met, and multi-center clinical application and popularization are facilitated.